PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ${\bf 7}$:

C12N 15/31, C07K 14/40, A61K 31/70, 38/16, C07K 16/14, G01N 33/50, C12Q 1/68

A2

(11) International Publication Number:

WO 00/09695

(43) International Publication Date:

24 February 2000 (24,02,00)

(21) International Application Number:

PCT/EP99/05991

(22) International Filing Date:

16 August 1999 (16.08.99)

(30) Priority Data:

9817796.7 98310694.9 14 August 1998 (14.08.98)

23 December 1998 (23.12.98)

GB EP

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CONTRERAS, Roland, Henri [BE/BE]; University of Gent, K.L. Ledeganckstraat 35, B–9000 Gent (BE). NELISSEN, Bart [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). DE BACKER, Marianne, Denise [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). LUYTEN, Walter, Herman, Maria, Louis [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B–2340 Beerse (BE). VIAENE, Jasmine, Elza [BE/BE]; University of Gent, K.L. Ledeganckstraat 35, B–9000 Gent (BE). LOGGHE, Marc, George [BE/BE]; University of Gent, K.L. Ledeganckstraat 35, B–9000 Gent (BE).

(74) Agent: BOULT WADE TENNANT; 27 Furnival Street, London EC4A 1PQ (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

Without international search report and to be republished upon receipt of that report.

(54) Title: DRUG TARGETS IN CANDIDA ALBICANS

(57) Abstract

The present invention is concerned with a method of identifying compounds which selectively modulate expression of polypeptides which are crucial for growth and survival of Candida albicans, which method comprises: (a) contacting a compound to be tested with one or more Candida albicans cells having a mutation in a nucleic acid molecule corresponding to the sequences according to any of claims 1 to 8 which mutation results in overexpression or underexpression of said polypeptides, in addition to contacting one or more wild type Candida albicans cells with said compound, (b) monitoring the growth and/or activity of said mutated cell compared to said wild type; wherein differential growth or activity of said one or more mutated Candida cells is indicative of selective action of said compound on a polypeptide or another polypeptide in the same or a parallel pathway. Also disclosed in the present invention are compounds identified and the sequences themselves which are critical for survival and growth of Candida albicans.